Results 111 to 120 of about 62,474 (297)

Unusual visual loss in a patient with exudative macular degeneration

American Journal of Ophthalmology Case Reports, 2022
Purpose: To describe a case of marked vision loss in a patient with neovascular age-related macular degeneration after choroidal neovascular membrane (CNV) improvement and stabilization.
Enoch T. Peng, Sean D. Adrean
doaj  

Consensus‐based recommendations for indications and procedures in retinal laser treatment of Telangiectatic capillaries (TelCaps) in vascular macular oedema: A Delphi study

Acta Ophthalmologica, EarlyView.
Abstract Purpose The identification of telangiectatic capillaries (TelCaps) in chronic macular oedema (ME) resistant to conventional intravitreal injections (IVIs) has renewed interest in focal laser treatment. However, the indications and modalities of this laser treatment remain to be clarified.
Marie‐Noëlle Delyfer, Jean‐François Girmens, Corinne Dot, Mohamed Bennani, Marie‐Benedicte Rougier, Stéphanie Baillif, Pascale Massin, Vincent Gualino, Michel Paques, Bénédicte Dupas   +9 more
wiley   +1 more source

Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration [PDF]

, 2017
Biomarkers can help unravel mechanisms of disease and identify new targets for therapy. They can also be useful in clinical practice for monitoring disease progression, evaluation of treatment efficacy, and risk assessment in multifactorial diseases ...
Dammeier, S. (Sascha), Delcourt, C. (Cécile), Hollander, A.I. (Anneke), Hoyng, C.B. (Carel), Jong, E.K. (Eiko) de, Kersten, E. (Eveline), Klaver, C.C.W. (Caroline), Lengyel, I. (Imre), Paun, C.C. (Codrut), Peto, T. (Tünde), Schellevis, R.L. (Rosa L.), Ueffing, M. (Marius)   +11 more
core   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source

Intravitreal bevacizumab for neovascular age-related macular degeneration

Philippine Journal of Ophthalmology, 2009
Objectives: Anti-vascular endothelial growth factor (anti-VEGF) drugs delivered intravitreally have been proven effective and safe for the treatment of patients diagnosed with neovascular age-related macular degeneration (ARMD).
Junn R. Pajarillo, MD, Harvey S. Uy,MD, Milagros H. Arroyo MD, MPH   +2 more
doaj  

Real‐World 10‐Year Outcomes of Anti‐VEGF Therapy for Neovascular Age‐Related Macular Degeneration: A Meta‐Analysis

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background This study examines the long‐term effectiveness of anti‐VEGF therapy in managing neovascular age‐related macular degeneration (nAMD). Despite the well‐established short‐term improvements of anti‐VEGF therapy, there is limited data on its continued efficacy over extended periods.
Kimberly Spooner, Geoffrey Broadhead, Samantha Fraser‐Bell, Thomas Hong, James G. Wong, Andrew A. Chang   +5 more
wiley   +1 more source

The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation [PDF]

, 2013
Background/Aim. Age-related macular degeneration (AMD) is a leading cause of the loss of central visual acuity in population older than 70 years. We can distinguish wet and dry form of AMD.
Cerović Vesna, Draganić Biljana, Janićijević-Petrović Mirjana, Petrović Nenad, Ristić Dragana, Vukosavljević Miroslav   +5 more
core   +1 more source

Retinal Vessel Traits and Age‐Related Eye Disease in the Canadian Longitudinal Study on Aging

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To cross‐sectionally and longitudinally examine whether retinal vessel traits are associated with glaucoma‐related outcomes (glaucoma, cup‐to‐disc ratio [CDR] and intraocular pressure [IOP]) and age‐related macular degeneration (AMD).
Alexis O'Neil, Roshan A. Welikala, Sarah Barman, Christopher G. Owen, Alicja R. Rudnicka, Mohan Rakesh, Marie‐Hélène Roy‐Gagnon, David Maberley, Ellen E. Freeman   +8 more
wiley   +1 more source

Real World Data Comparison of Standard Care vs SDM Laser Vision Protection Therapy for Prevention of Neovascular AMD

Clinical Ophthalmology, 2022
Jeffrey K Luttrull,1 Gerry Gray2 1Ventura County Retina Vitreous Medical Group, Ventura, CA, USA; 2Regulatory Pathways, Inc, Laguna Beach, CA, USACorrespondence: Jeffrey K Luttrull, Ventura County Retina Vitreous Medical Group, 3160 Telegraph Road, Suite
Luttrull JK, Gray G
doaj  

DISCOVER: 2-D Multiview Summarization of Optical Coherence Tomography Angiography for Automatic Diabetic Retinopathy Diagnosis [PDF]

Artificial Intelligence in Medicine 2024, 102803
Diabetic Retinopathy (DR), an ocular complication of diabetes, is a leading cause of blindness worldwide. Traditionally, DR is monitored using Color Fundus Photography (CFP), a widespread 2-D imaging modality. However, DR classifications based on CFP have poor predictive power, resulting in suboptimal DR management.
arxiv   +1 more source